HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Keratoplasty postoperative treatment update.

Abstract
Immunosuppressive therapy is the main postoperative treatment for keratoplasty, but there are considerable differences in protocols for the use of steroids and other immunosuppressants. Therefore, we conducted 2 prospective randomized clinical trials and 1 prospective nonrandomized clinical trial on keratoplasty postoperative treatment. One study evaluated the efficacy and safety of long-term topical corticosteroids after a penetrating keratoplasty was performed. Patients who underwent keratoplasty and maintained graft clarity for >1 year were randomly assigned to either a steroid or a no-steroid group. At the 12-month follow-up, the no-steroid group developed significantly more endothelial rejection than did the steroid group. A second study elucidated the effectiveness and safety of systemic cyclosporine in high-risk corneal transplantation. The patients were assigned to a systemic cyclosporine or control group. At a mean follow-up of 42.7 months, no difference was observed in the endothelial rejection rates and graft clarity loss between the 2 groups. A third study elucidated the effectiveness and the safety of systemic tacrolimus in high-risk corneal transplantation. Of 11 consecutive eyes decompensated despite systemic cyclosporine treatment, there was no irreversible rejection in eyes treated with tacrolimus, which was significantly better than in previous penetrating keratoplasty with systemic cyclosporine treatment. Prognosis after keratoplasty in patients with keratoconus is relatively good, but special attention is required for patients with atopic dermatitis. Postkeratoplasty atopic sclerokeratitis (PKAS) is a severe form of sclerokeratitis after keratoplasty in atopic patients. Our retrospective study showed that 35 eyes of 29 patients from a total of 247 keratoconus eyes undergoing keratoplasty were associated with atopic dermatitis, of which 6 eyes of 5 patients developed PKAS. Eyes with PKAS had a significantly higher incidence of atopic blepharitis and preoperative corneal neovascularization, and therefore, we suggest systemic corticosteroids or cyclosporine to prevent PKAS in such high-risk cases.
AuthorsMachiko Shimmura-Tomita, Shigeto Shimmura, Yoshiyuki Satake, Seika Shimazaki-Den, Masahiro Omoto, Kazuo Tsubota, Jun Shimazaki
JournalCornea (Cornea) Vol. 32 Suppl 1 Pg. S60-4 (Nov 2013) ISSN: 1536-4798 [Electronic] United States
PMID24104936 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenal Cortex Hormones
  • Immunosuppressive Agents
  • Cyclosporine
  • Tacrolimus
Topics
  • Adrenal Cortex Hormones (adverse effects, therapeutic use)
  • Adult
  • Aged
  • Aged, 80 and over
  • Clinical Trials as Topic
  • Cyclosporine (adverse effects, therapeutic use)
  • Dermatitis, Atopic (complications)
  • Female
  • Graft Rejection (prevention & control)
  • Humans
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Keratoplasty, Penetrating
  • Male
  • Middle Aged
  • Postoperative Care (methods)
  • Prospective Studies
  • Tacrolimus (adverse effects, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: